Concert Pharmaceuticals Inc $ 6.21 0.05 (0.81%)
Volume:
369,372
Avg Vol (1m):
562,147
Market Cap $:
199.80 Mil
Enterprise Value $:
83.86 Mil
PE Ratio:
0.00
PB Ratio:
1.54
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 8.25 | ||
| Equity-to-Asset | 0.82 | ||
| Debt-to-Equity | 0.12 | ||
| Debt-to-EBITDA | -0.23 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 1.75 | ||
| Beneish M-Score | 3.31 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -919.35 | ||
| Net Margin % | -946.17 | ||
| ROE % | -56.72 | ||
| ROA % | -46.19 | ||
| ROC (Joel Greenblatt) % | -448.49 | ||
| 3-Year Revenue Growth Rate | -65.5 |
CNCE
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.54 | ||
| PS Ratio | 24.73 | ||
| EV-to-EBIT | -1.16 | ||
| EV-to-EBITDA | -1.18 | ||
| EV-to-Revenue | 10.61 | ||
| Current Ratio | 14.02 | ||
| Quick Ratio | 14.02 | ||
| Days Sales Outstanding | 31.69 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.5 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 1.55 | ||
| Earnings Yield (Greenblatt) % | -86.78 |